Compare PARR & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PARR | WGS |
|---|---|---|
| Founded | 1984 | 2017 |
| Country | United States | United States |
| Employees | N/A | 1300 |
| Industry | Integrated oil Companies | Retail: Computer Software & Peripheral Equipment |
| Sector | Energy | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 2.6B |
| IPO Year | 2000 | N/A |
| Metric | PARR | WGS |
|---|---|---|
| Price | $64.39 | $65.73 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | $57.00 | ★ $130.71 |
| AVG Volume (30 Days) | ★ 1.5M | 662.0K |
| Earning Date | 05-05-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1313.56 | N/A |
| EPS | ★ 7.16 | N/A |
| Revenue | ★ $2,443,066,000.00 | N/A |
| Revenue This Year | N/A | $29.98 |
| Revenue Next Year | $4.73 | $26.04 |
| P/E Ratio | ★ $9.06 | $1,251.58 |
| Revenue Growth | ★ 30.99 | N/A |
| 52 Week Low | $12.17 | $55.17 |
| 52 Week High | $66.75 | $170.87 |
| Indicator | PARR | WGS |
|---|---|---|
| Relative Strength Index (RSI) | 68.95 | 40.59 |
| Support Level | $34.55 | $61.55 |
| Resistance Level | N/A | $95.75 |
| Average True Range (ATR) | 3.57 | 3.97 |
| MACD | 0.18 | 0.08 |
| Stochastic Oscillator | 87.18 | 46.91 |
Par Pacific Holdings Inc is an oil and gas company that manages and maintains interests in energy and infrastructure businesses. The company has three reportable segments: Refining. Under its refining business, the company produces ultra-low-sulfur diesel, gasoline, jet fuel, marine fuel, LSFO, and other associated refined products. Its Retail includes operating licenses out brands to serve the retail consumer. Through the Logistics segment, crude shipments are delivered to the refineries, in addition to finished products that are exported. It generates maximum revenue from the Refining segment.
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.